Aim. To evaluate the peripapillary retinal nerve fiber layer (RNFL) changes in retinitis pigmentosa (RP) patients using spectral domain optic coherence tomography (Sd-OCT). Methods. We retrospectively examined medical records of forty-four eyes of twenty-two RP patients. The results were also compared with those of previously reported forty-four eyes of twenty-two normal subjects (controls). Records of average and four quadrants peripapillary RNFL thickness measurements using Sd-OCT were assessed. Results. In RP patients the mean RNFL thickness was 97.57 ± 3.21 μm. The RNFL in the superior, temporal, nasal, and inferior quadrants was 119.18 ± 4.47 μm, 84.68 ± 2.31 μm, 75.09 ± 3.34 μm, and 113.88 ± 4.25 μm, respectively. While the thinning of RNFL was predominantly observed in the inferior quadrant, the thickening was mostly noted in temporal quadrant. The differences between mean, superior, and nasal quadrant RNFL thicknesses were not statistically significant when compared with control group. The RP patients had thinner inferior quadrant and thicker temporal quadrant than control group (p < 0.05). Conclusion. Sd-OCT is highly sensitive and effective instrument to detect RNFL changes in RP patients. RNFL measurements can provide information about the progression of retinitis pigmentosa and may provide prognostic indices for future treatment modalities.
Re sults: The mean age was 25 (1-56) years. Twelve patients (80%) were males and 3 (20%) were female. Twelve (80%) eyes presented with lower canalicular laceration, 1 (6.7%) eye-with upper canalicular laceration, and 2 (13.3%) eyes had bicanalicular laceration. Five of injuries (33%) were due direct sharp objects and 10 of injuries (66%) occurred due to blunt trauma. Six of patients were operated under general anesthesia and 9 of patients were operated under local anesthesia. The mean time duration between canalicular injury and surgery was found to be 14 hours (4-39 hours). The mean duration of the tubes' residence time was 5.26 months (1-6 months). Patients were followed averagely 14 months (6-32 months) in the postoperative period. The open status of lavage was considered as anatomical success, and the absence of fluorescein dye pooling and epiphora was considered as functional success. Except for 1 patient with tube protrusion in the early postoperative first month, anatomical and functional success was achieved in 14 patients (93.3%) during the follow-up period. Conclusion: After traumatic canalicular lacerations, Monoka ® tube intubation is an easily applicable and effective method with low risk of damage. (Turk J Ophthalmol 2015; 45: 14-17)
Objective: To evaulate the efficacy of botulinum toxin A injection and factors affecting the treatment in strabismus. Material and Methods: Botulinum toxin A administered 43 patients with the diagnosis of horizontal deviation in 26'sında (%60,5) ezotropya mevcutken, 17'sinde (%39,5) ekzotropta vardı. Hastaların 16'sı (%37,2) rezidüel şaşılık, 19'u (%44,2) paralitik şaşılık, 8'i (%18,6) ise konsekütiv şaşılık idi. Otuz (%69,[8][9][10][11][12][13][14][15][16][17][18][19][20] 13 (%30,2)
Objective: To evaluate the efficacy of intravitreal ranibizumab treatment and factors affecting the treatment in neovascular type age-related macular degeneration Methods: Ranibizumab injected 60 eyes of 60 patients with the diagnosis of neovascular age-related macular degeneration in our clinic were analyzed retrospectively. After three consecutive 3-month follow-up dose injection, decision to perform re-injections was according to best corrected visual acuity, fundus fluorescein angiography and optical coherence tomography findings in consecutive month follow-up. Patients were evaluated in terms of number of ranibizumab injections, pre-treatment and follow-up best-corrected visual acuity, central macular thickness, factors affecting the treatment and recurrence.Results: 30 (50%) of patients were male and 30 (50%) were women with a mean age of 67 ± 9.14 (50-84). While pretreatment visual acuity average of the cases was 1.12 ± 0.69 logMAR, at the end of 12th month was 0.92 ± 0.63 logMAR. While pre-treatment mean central macular thickness was 343.1 ± 97 µm, in the 12 th month was 286 ± 75.5 µm. While the first 3 injections were enough in 20 (33.3%) eyes, but 40 (66.7%) eyes had to be re-injected. Average number of injections was 4.23 ± 1.21. While there was no significant correlation between recent functional and anatomical success with age, gender, type of lens and membrane type, more vision gain was obtained in patients with initial lower visual acuity. The age of patients, pre-treatment visual acuity, membrane type were found to have no significant effect on recurrence rate. Membranes with classic component required more injection than occult type. Conclusion:After intravitreal injection of ranibizumab which is safe and effective in neovascular type of age-related macular degeneration more vision gain was obtained in patients with initial lower visual acuity and presence of classic component initial higher visual acuity, lower age required more injection.Key words: Age-related macular degeneration, ranibizumab, vascular endothelial growth factor ÖZET Amaç: Neovasküler tip yaşa bağlı maküla dejenerasyonu (YBMD) nedeniyle uygulanan intravitreal ranibizumab enjeksiyonunun etkinliğini ve tedavi üzerinde etkili olan faktörleri değerlendirmek Yöntemler: Kliniğimizde neovasküler tip YBMD'de intravitreal ranibizumab enjeksiyonu uygulanan 60 hastanın 60 gözü retrospektif olarak incelendi. Hastalara birer ay arayla 3 doz enjeksiyon yapıldıktan sonra aylık takiplerde en iyi düzeltilmiş görme keskinliği (EİDGK), fundus fluoresein anjiografi (FFA) ve optik kohorens tomografi (OKT) bulgularına göre enjeksiyon tekrarı uygulandı. Hastalar; enjeksiyon sayısı, takip süresi, tedavi öncesi ve kontrollerdeki EİDGK, santral makula kalınlığı (SMK), başarıda, rekürrens üzerinde etkili olan faktörler açısından değerlendirildi. Bulgular: 30'u (%50) erkek 30'u (%50) kadın olan hastaların ortalama yaşı 67±9,14 (50-84) yıl idi. Olgulardaki tedavi öncesi ortalama görme keskinliği 1,12 ± 0,69 logMAR iken 12. ayda ise, 0,92 ± 0,63 lo...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.